GSK Agrees to Buy Nuvalent for $10.6 Billion
GSK agreed to buy Nuvalent in a deal valued at $10.6 billion, adding a biotech firm that's developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise. Sam Fazeli of Bloomberg Intelligence has more.
_1417563_640x360_2503007299812-640x360.webp&w=3840&q=75)
_1416725_640x360_2502846019902-640x360.webp&w=3840&q=75)
_1414147_640x360_2502467139706-640x360.webp&w=3840&q=75)

_1401896_640x360_2500436035532-640x360.webp&w=3840&q=75)
_1399805_640x360_2500028483712-640x360.webp&w=3840&q=75)

_1394202_640x360_2498899523563-640x360.webp&w=3840&q=75)
_1394083_640x360_2498883139600-640x360.webp&w=3840&q=75)
